Am J Psychiatry 159:1146-1154, July 2002
© 2002 American Psychiatric Association
Combination of a Mood Stabilizer With Risperidone or Haloperidol for Treatment of Acute Mania: A Double-Blind, Placebo-Controlled Comparison of Efficacy and Safety
Gary S. Sachs, M.D.,
Fred Grossman, D.O.,
S. Nassir Ghaemi, M.D.,
Akiko Okamoto, Sc.D., and
Charles L. Bowden, M.D.
OBJECTIVE: The study assessed the efficacy and safety of risperidone as an adjunctive agent to mood stabilizers in the treatment of acute mania. METHOD: This 3-week randomized, double-blind, placebo-controlled study included 156 bipolar disorder patients with a current manic or mixed episode who received a mood stabilizer (lithium or divalproex) and placebo, risperidone, or haloperidol. The primary efficacy measure was the Young Mania Rating Scale. Other assessments used the Brief Psychiatric Rating Scale, the Clinical Global Impression scale, and safety measures. RESULTS: The trial was discontinued by 25 (49%) of the 51 placebo group patients, 18 (35%) of the 52 risperidone group patients, and 28 (53%) of the 53 haloperidol group patients. Mean modal doses were 3.8 mg/day (SD=1.8) of risperidone and 6.2 mg/day (SD=2.9) of haloperidol. Significantly greater reductions in Young Mania Rating Scale scores at endpoint and over time were seen in the risperidone group and in the haloperidol group, compared with the placebo group. Young Mania Rating Scale total scores improved with risperidone and with haloperidol both in patients with psychotic features and in those without psychotic features at baseline. Extrapyramidal Symptom Rating Scale total scores at endpoint were significantly higher in the haloperidol patients than in the placebo patients. Antiparkinsonian medications were received by 8%, 17%, and 38% of patients in the placebo, risperidone, and haloperidol groups, respectively. CONCLUSIONS: Risperidone plus a mood stabilizer was more efficacious than a mood stabilizer alone, and as efficacious as haloperidol plus a mood stabilizer, for the rapid control of manic symptoms and was well tolerated.
This article has been cited by other articles:
|
|
|
|
 
F. M. Sanchez and M. H. Zisselman
Treatment of Psychiatric Symptoms Associated With Neurosyphilis
Psychosomatics,
October 1, 2007;
48(5):
440 - 445.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
References
PsychiatryOnline CME,
May 1, 2007;
2007(1):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
H. Scherk, F. G. Pajonk, and S. Leucht
Second-Generation Antipsychotic Agents in the Treatment of Acute Mania: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Arch Gen Psychiatry,
April 1, 2007;
64(4):
442 - 455.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Sachs
Bipolar Disorder Clinical Synthesis: Where Does the Evidence Lead?
Focus,
January 1, 2007;
5(1):
3 - 13.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. A. Hirschfeld
Guideline Watch (November 2005): Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd Edition
Focus,
January 1, 2007;
5(1):
34 - 39.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Bibliography BIPOLAR DISORDER
Focus,
January 1, 2007;
5(1):
40 - 43.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Khanna, E. Vieta, B. Lyons, F. Grossman, M. Kramer, and M. Eerdekens
Authors' reply
The British Journal of Psychiatry,
May 1, 2006;
188(5):
490 - 491.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. N Nguyen and S. K Guthrie
Risperidone Treatment of Bipolar Mania
Ann. Pharmacother.,
April 1, 2006;
40(4):
674 - 682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A Marken and R. W Pies
Emerging Treatments for Bipolar Disorder: Safety and Adverse Effect Profiles
Ann. Pharmacother.,
February 1, 2006;
40(2):
276 - 285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Khanna, E. Vieta, B. Lyons, F. Grossman, M. Eerdekens, and M. Kramer
Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study
The British Journal of Psychiatry,
September 1, 2005;
187(3):
229 - 234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. R. Krishnan
Psychiatric and Medical Comorbidities of Bipolar Disorder
Psychosom Med,
January 1, 2005;
67(1):
1 - 8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Citrome, R. Josiassen, N. Bark, D. E. Salazar, and S. Mallikaarjun
Pharmacokinetics of Aripiprazole and Concomitant Lithium and Valproate
J. Clin. Pharmacol.,
January 1, 2005;
45(1):
89 - 93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. SUNDARARAJAN and A. K. JAINER
A Mood Stabilizer With Risperidone or Haloperidol for Mania
Am J Psychiatry,
November 1, 2004;
161(11):
2139 - 2140.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M.A. Hirschfeld, P. E. Keck Jr., M. Kramer, K. Karcher, C. Canuso, M. Eerdekens, and F. Grossman
Rapid Antimanic Effect of Risperidone Monotherapy: A 3-Week Multicenter, Double-Blind, Placebo-Controlled Trial
Am J Psychiatry,
June 1, 2004;
161(6):
1057 - 1065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. T. Lewis
Demystifying the Disease State: Understanding Diagnosis and Treatment Across the Bipolar Spectrum
Journal of the American Psychiatric Nurses Association,
June 1, 2004;
10(3_suppl):
S6 - S15.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Tohen, J. F. Goldberg, A. M. Gonzalez-Pinto Arrillaga, J. M. Azorin, E. Vieta, M.-C. Hardy-Bayle, W. B. Lawson, R. A. Emsley, F. Zhang, R. W. Baker, et al.
A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania
Arch Gen Psychiatry,
December 1, 2003;
60(12):
1218 - 1226.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Goodwin
Evidence-Based Guidelines for Treating Bipolar Disorder: Recommendations from the British Association for Psychopharmacology
J Psychopharmacol,
June 1, 2003;
17(2):
149 - 173.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. W. Jefferson
Bipolar Disorders: A Brief Guide to Diagnosis and Treatment
Focus,
January 1, 2003;
1(1):
7 - 14.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2002
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
